High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Massachusetts General Hospital, City Of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Nebraska Medical Center, Beth Israel Deaconess Medical Center, The University of Texas MD Anderson Cancer Center, University of Alabama at Birmingham, Juno Therapeutics (United States), Fred Hutch Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2791416449